Application of lipid nanoparticles to ocular drug delivery

References

• Sah AK, Suresh PK. Recent advances in ocular drug delivery, with special emphasis on lipid based nanocarriers. Recent Pat Nanotechnol. 2015;9(2):94–105.
   PubMed Web of Science ®Google Scholar
• Pignatello R, Carbone C, Puglia C, et al. Ophthalmic applications of lipid-based drug nanocarriers: an update of research and patenting activity. Ther Deliv. 2015;6(11):1297–1318.
   PubMedGoogle Scholar
• Puglia C, Offerta A, Carbone C, et al. Lipid nanocarriers (LNC) and their applications in ocular drug delivery. Curr Med Chem. 2015;22(13):1589–1602.
   PubMed Web of Science ®Google Scholar
• Malhotra A, Minja FJ, Crum A. Ocular anatomy and cross-sectional imaging of the eye. Semin Ultrasound CT MRI. 2011;32(1):2–13.
   PubMed Web of Science ®Google Scholar
• Patil BB, Dowd TC. Physiological functions of the eye. Curr Anaesth Crit Care. 2000;11(6):293–298.
   Google Scholar
• Presland A. Applied ocular physiology and anatomy. Anaesth Intens Care Med. 2007;8(9):379–382.
   Google Scholar
• Presland A, Price J. Ocular anatomy and physiology relevant to anaesthesia. Anaesth Intens Care Med. 2014;15(1):20–25.
   Google Scholar
• Wichmann W, Müller-Forell W. Anatomy of the visual system. Eur J Radiol. 2004;49(1):8–30.
   PubMed Web of Science ®Google Scholar
• Hodges RR, Dartt DA. Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract Mucins. Exp Eye Res. 2013;117:62–78.
   PubMed Web of Science ®Google Scholar
• Bron AJ, Tiffany JM, Gouveia SM, et al. Functional aspects of the tear film lipid layer. Exp Eye Res. 2004;78:347–360.
   PubMed Web of Science ®Google Scholar
• Dartt DA. Interaction of EGF family growth factors and neurotransmitters in regulating lacrimal gland secretion. Exp Eye Res. 2004;78:337–345.
   PubMed Web of Science ®Google Scholar
• Gan L, Wang J, Jiang M, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today. 2013;18:290–297.
   PubMed Web of Science ®Google Scholar
• Goel M, Picciani RG, Lee RK, et al. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010;3(4):52–59.
   Google Scholar
• Meek KM. The cornea and Sclera. In: Fratzl P, editor. Collagen: structure and mechanics. New York (NY): Springer Science+Business Media, LLC; 2008.
   Google Scholar
• Presland A, Myatt J. Ocular anatomy and physiology relevant to anaesthesia. Anaesth Intens Care Med. 2010;11:438–443.
   Google Scholar
• Murthy KR, Goel R, Subbannayya Y, et al. Proteomic analysis of human vitreous humor. Clin Proteomics. 2014;11(1):29.
   PubMed Web of Science ®Google Scholar
• Souto EB, Doktorovova S, Gonzalez-Mira E, et al. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr Eye Res. 2010;35(7):537–552.
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol. 2011;21:S3–S9.
   PubMed Web of Science ®Google Scholar
• Campbell M, Humphries P. The blood-retina barrier: tight junctions and barrier modulation. Adv Exp Med Biol. 2012;763:70–84.
   PubMed Web of Science ®Google Scholar
• Eljarrat-Binstock E, Pe’er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res. 2010;27:530–543.
   PubMed Web of Science ®Google Scholar
• Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today. 2008;13:135–143.
   PubMed Web of Science ®Google Scholar
• Mannermaa E. In Vitro model of retinal pigment epithelium for use in drug delivery studies. Kuopio: University of Eastern Finland; 2010.
   Google Scholar
• Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther. 2003;3:45–56.
   PubMed Web of Science ®Google Scholar
• Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol. 2007;18:235–239.
   PubMed Web of Science ®Google Scholar
• Wadhwa S, Paliwal R, Paliwal SR, et al. Nanocarriers in ocular drug delivery: an update review. Curr Pharm Des. 2009;15:2724–2750.
   PubMed Web of Science ®Google Scholar
• Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145(3):182–195.
   PubMed Web of Science ®Google Scholar
• Bucolo C, Drago F, Salomone S. Ocular drug delivery: a clue from nanotechnology. Front Pharmacol. 2012;3:2002–2004.
   Web of Science ®Google Scholar
• Thrimawithana TR, Young S, Bunt CR, et al. Drug delivery to the posterior segment of the eye. Drug Discov Today. 2011;16:271–277.
   Web of Science ®Google Scholar
• Bäckström G, Lundberg B, Behndig A. Intracameral acetylcholine effectively contracts pupils after dilatation with intracameral mydriatics. Acta Ophthalmol. 2013;91(2):123–126.
   PubMed Web of Science ®Google Scholar
• Wadhwa S, Paliwal R, Paliwal SR, et al. Nanocarriers in ocular drug delivery: an update review. Curr Pharm Des. 2009;15:2724–2750.
   PubMed Web of Science ®Google Scholar
• Ausayakhun S, Yuvaves P, Ngamtiphakom S, et al. Treatment of cytomegalovirus retinitis in AIDS patients with intravitreal ganciclovir. J Med Assoc Thai. 2005;88:S15–S20.
   PubMedGoogle Scholar
• Mikhail M, Sallam A. Novel intraocular therapy in non-infectious uveitis of the posterior segment of the eye. Med Hypothesis Discov Innov Ophthalmol. 2013;2(4):113–120.
   PubMedGoogle Scholar
• Solinís MÁ, Del Pozo-Rodríguez A, Apaolaza PS, et al. Treatment of ocular disorders by gene therapy. Eur J Pharm Biopharm. 2015;95(Pt B):331–342.
   PubMed Web of Science ®Google Scholar
• Bloquel C, Bourges JL, Touchard E, et al. Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Deliver Rev. 2006;58:1224–1242.
   PubMed Web of Science ®Google Scholar
• Bucolo C, Drago F. Carbon monoxide and the eye: implications for glaucoma therapy. Pharmacol Ther. 2011;130(2):191–201.
   PubMed Web of Science ®Google Scholar
• Zhou HY, Hao JL, Wang S, et al. Nanoparticles in the ocular drug delivery. Int J Ophthalmol. 2013;6(3):390–396.
   PubMed Web of Science ®Google Scholar
• Elbadawy HM, Gailledrat M, Desseaux C, et al. Targeting herpetic keratitis by gene therapy. J Ophthalmol. 2012;2012:594869.
   PubMed Web of Science ®Google Scholar
• Cho YK, Uehara H, Young JR, et al. Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci. 2012;53(4):2328–2336.
   PubMed Web of Science ®Google Scholar
• Hattori M, Shimizu K, Katsumura K, et al. Effects of all-trans retinoic acid nanoparticles on corneal epithelial wound healing. Graefes Arch Clin Exp Ophthalmol. 2012;250(4):557–563.
   PubMed Web of Science ®Google Scholar
• Kim NJ, Harris A, Gerber A, et al. Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine. Br J Ophthalmol. 2014;98:427–431.
   PubMed Web of Science ®Google Scholar
• Bucolo C, Platania CB, Reibaldi M, et al. Controversies in glaucoma: current medical treatment and drug development. Curr Pharm Des. 2015;21(32):4673–4681.
   PubMed Web of Science ®Google Scholar
• Bucolo C, Salomone S, Drago F, et al. Pharmacological management of ocular hypertension: current approaches and future prospective. Curr Opin Pharmacol. 2013;13(1):50–55.
   PubMed Web of Science ®Google Scholar
• Musumeci T, Bucolo C, Carbone C, et al. Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in Rabbits. Int J Pharm. 2013;440(2):135–140.
   PubMed Web of Science ®Google Scholar
• Jo DH, Lee TG, Kim JH. Nanotechnology and nanotoxicology in retinopathy. Int J Mol Sci. 2011;12:8288–8301.
   PubMed Web of Science ®Google Scholar
• Preeti K, Suresh M, Abhishek K. Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions. Expert Opin Drug Deliv. 2014;11(11):1747–1768.
   PubMed Web of Science ®Google Scholar
• Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10:505–512.
   PubMed Web of Science ®Google Scholar
• Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003;217:89–98.
   PubMed Web of Science ®Google Scholar
• Solanki S, Rathi M, Khanduja S, et al. Recent trends: medical management of infectious keratitis. Oman J Ophthalmol. 2015;8(2):83–85.
   PubMedGoogle Scholar
• Keynan Y, Finkelman Y, Lagacé-Wiens P. The microbiology of endophthalmitis: global trends and a local perspective. Eur J Clin Microbiol Infect Dis. 2012;31:2879–2886.
   PubMed Web of Science ®Google Scholar
• Camber O. Studies on corneal permeability and an evaluation of prostaglandin F(2α) pro-drugs and sodium hyaluronate. Acta Pharm Suec. 1988;25(3):181.
   Google Scholar
• Surajit D. Corneal cell culture models: a tool to study corneal drug absorption. Expert Opin Drug Metab Toxicol. 2011;7(5):529–532.
   PubMed Web of Science ®Google Scholar
• Sarmento B, Andrade F, Baptista Da Silva S, et al. Cell-based in vitro models for predicting drug permeability. Expert Opin Drug Metab Toxicol. 2012;8(5):607–621.
   PubMed Web of Science ®Google Scholar
• Vinardell MP, Mitjans M. Alternative methods for eye and skin irritation tests: an overview. J Pharm Sci. 2008;97:46–59.
   PubMed Web of Science ®Google Scholar
• Marcondes PF, Rodrigues EB, Maia M. Retinal and ocular toxicity in ocular application of drugs and chemicals – part I: animal models and toxicity assays. Ophthalmic Res. 2010;44:82–104.
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res. 2010;29:500–519.
   PubMed Web of Science ®Google Scholar
• Weber BH, Schrewe H, Molday LL, et al. Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure. Proc Natl Acad Sci USA. 2002;99:6222–6227.
   PubMed Web of Science ®Google Scholar
• Veleri S, Lazar CH, Chang B, et al. Biology and therapy of inherited retinal degenerative disease: insights from mouse models. Dis Model Mech. 2015;8:109–129.
   PubMed Web of Science ®Google Scholar
• Mowat FM, Breuwer AR, Bartoe JT, et al. RPE65 gene therapy slows cone loss in Rpe65-deficient dogs. Gene Ther. 2013;20(5):545–555.
   PubMed Web of Science ®Google Scholar
• Rivas MA, Vecino E. Animal models and different therapies for treatment of retinitis pigmentosa. Histol Histopathol. 2009;24(10):1295–1322.
   PubMed Web of Science ®Google Scholar
• Ako-Adounvo AM, Nagarwal RC, Oliveira L, et al. Recent patents on ophthalmic nanoformulations and therapeutic implications. Recent Pat Drug Deliv Formul. 2014;8:193–201.
   PubMedGoogle Scholar
• Almeida H, Amaral MH, Lobão P, et al. Applications of polymeric and lipid nanoparticles in ophthalmic pharmaceutical formulations: present and future considerations. J Pharm Pharm Sci. 2014;17(3):278–293.
   PubMed Web of Science ®Google Scholar
• Kothuri MK, Pinnamaneni S, Das NG, et al. Microparticles and nanoparticles in ocular drug delivery. In: Mitra AK editor. Ophthalmic drug delivery systems. New York (NY): Informa Healthcare; 2003. p. 437–466.
   Google Scholar
• Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv. 2010;17:467–489.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196.
   PubMed Web of Science ®Google Scholar
• Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv. 2012;9(5):497–508.
   PubMed Web of Science ®Google Scholar
• Müller RH, Olbrich C. Lipid matrix-drug conjugates particle for controlled release of active ingredient. US6770299. 2004.
   Google Scholar
• Cavalli R, Gasco MR, Chetoni P, et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;238:241–245.
   PubMed Web of Science ®Google Scholar
• JHao J, Fang X, Zhou Y, et al. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a box-behnken design. Int J Nanomedicine. 2011;6:683–692.
   PubMed Web of Science ®Google Scholar
• Kalam MA, Sultana Y, Ali A, et al. Part I: development and optimization of solid-lipid nanoparticles using box-behnken statistical design for ocular delivery of gatifloxacin. J Biomed Mater Res A. 2013;101A(6:1813–1827.
   Web of Science ®Google Scholar
• Kalam MA, Sultana Y, Ali A, et al. Part II: enhancement of transcorneal delivery of gatifloxacin by solid lipid nanoparticles in comparison to commercial aqueous eye drops. J Biomed Mater Res A. 2013;101A(6:1828–1836.
   Web of Science ®Google Scholar
• Kalam MA, Sultana Y, Ali A, et al. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Targ. 2010;18(3):191–204.
   PubMed Web of Science ®Google Scholar
• Salman M, Ahad A, Aslam M, et al. Application of box–behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery : optimization, in vitro release, ocular tolerance, and antibacterial activity. Int J Biol Macromolec. 2016;85:258–270.
   PubMed Web of Science ®Google Scholar
• Mohanty B, Majumdar D, Mishra S, et al. Development and characterization of itraconazole loaded solid lipid nanoparticles for ocular delivery. Pharm Dev Technol. 2015;20(4):458–464.
   PubMed Web of Science ®Google Scholar
• Kakkar S, Karuppayil SM, Raut JS, et al. Lipid-polyethylene glycol based nano-ocular formulation of ketoconazole. Int J Pharm. 2015;495(1):276–289.
   PubMed Web of Science ®Google Scholar
• Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm. 2013;39(4):508–519.
   PubMed Web of Science ®Google Scholar
• Attama AA, Reichl S, Muller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm. 2008;355:307–313.
   PubMed Web of Science ®Google Scholar
• Xiang L, Nie S-F, Kong J, et al. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008;363:177–182.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Mira E, Egea MA, Garcia ML, et al. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B Biointerfaces. 2010;81:412–421.
   PubMed Web of Science ®Google Scholar
• Qiuhua L, Junming Z, Xiangrong Z. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm. 2011;403:185–191.
   PubMed Web of Science ®Google Scholar
• Hippalgaonkar K, Adelli GR, Hippalgaonkar K, et al. Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation. J Ocul Pharmacol Ther. 2013;29(2):216–228.
   PubMed Web of Science ®Google Scholar
• Araújo J, Gonzalez-Mira E, Egea MA, et al. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm. 2010;393:167–175.
   PubMed Web of Science ®Google Scholar
• Araujo J, Nikoli S, Egea MA, et al. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf B Biointerfaces. 2011;88:150–157.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang X, Haoyun W, et al. Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Dev Ind Pharm. 2011;37(4):475–481.
   PubMed Web of Science ®Google Scholar
• Liu C-H, Huang Y-C, Jhang J-W, et al. Quercetin delivery to porcine cornea and sclera by solid lipid nanoparticles and nanoemulsion. RSC Adv. 2015;5:100923–100933.
   Web of Science ®Google Scholar
• Fangueiro JF, Calpena AC, Clares B, et al. Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): in vivo, in vitro and EX Vivo studies. Int J Pharm. 2016;502(1–2):161–169.
   PubMed Web of Science ®Google Scholar
• Arana L, Salado C, Vega S, et al. Solid lipid nanoparticles for delivery of Calendula officinalis extract. Colloids Surf B Biointerfaces. 2015;135:18–26.
   PubMed Web of Science ®Google Scholar
• Shen J, Deng Y, Jin X, et al. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution. Int J Pharm. 2010;402:248–253.
   PubMed Web of Science ®Google Scholar
• Başaran E, Demirel M, Sırmagül B, et al. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul. 2010;27(1):37–47.
   PubMed Web of Science ®Google Scholar
• Battaglia L, D’Addino I, Peira E, et al. Solid lipid nanoparticles prepared by coacervation method as vehicles for ocular cyclosporine. J Drug Del Sci Tech. 2012;22(2):125–130.
   Web of Science ®Google Scholar
• Gokce EH, Sandri G, Bonferoni MC, et al. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm. 2008;364:76–86.
   PubMed Web of Science ®Google Scholar
• Niu M, Shi K, Sun Y, et al. Preparation of CyA-loaded solid lipid nanoparticles and application on ocular preparations. J Drug Del Sci Tech. 2008;18(4):293–297.
   Web of Science ®Google Scholar
• Shen J, Wang Y, Ping Q et al. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release. 2009;137:217–223.
   PubMed Web of Science ®Google Scholar
• Attama AA, Reichl S, Müller-Goymann CC. Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr Eye Res. 2009;34:698–705.
   PubMed Web of Science ®Google Scholar
• Wang F, Chen L, Zhang D, et al. Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study. J Drug Target. 2014;22(9):849–858.
   PubMed Web of Science ®Google Scholar
• Cavalli R, Morel S, Gasco MR, et al. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. Int J Pharm. 1995;117:243–246.
   Web of Science ®Google Scholar
• Leonardi A, Bucolo C, Drago F, et al. Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in Rabbit. Int J Pharm. 2015;478(1):180–186.
   PubMed Web of Science ®Google Scholar
• El-Salamouni NS, Farid RM, El-Kamel AH, et al. Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Int J Pharm. 2015;496(2):976–983.
   PubMed Web of Science ®Google Scholar
• Delgado D, Del Pozo-Rodríguez A, Solinís MÁ, et al. Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis. Hum Gene Ther. 2011 ;23(4):345–355.
   Web of Science ®Google Scholar
• Apaolaza PS, Delgado D, Del Pozo-Rodríguez A, et al. A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases. Int J Pharm. 2014;465:413–426.
   PubMed Web of Science ®Google Scholar
• Apaolaza PS, Del Pozo-Rodríguez A, Torrecilla J, et al. Solid lipid nanoparticle-based vectors intended for the treatment of X-linked juvenile retinoschisis by gene therapy: in vivo approaches in Rs1h-deficient mouse model. J Control Release. 2015;217:273–283.
   PubMed Web of Science ®Google Scholar
• Apaolaza, Del Pozo-Rodríguez A, Solinís MA, et al. Structural recovery of the retina in a retinoschisin-deficient mouse after gene replacement therapy by solid lipid nanoparticles. Biomaterials. 2016;90:40–49.
   PubMed Web of Science ®Google Scholar
• Hao J, Wang X, Bi Y, et al. Fabrication of a composite system combining solid lipid nanoparticles and thermosensitive hydrogel for challenging ophthalmic drug delivery. Colloids Surf B Biointerfaces. 2014;114:111–120.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Bucolo C, Romano GL, et al. Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. Intl J Pharm. 2014;470:133–140.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Felt-Baeyens O, Besseghir K, et al. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307–318.
   PubMed Web of Science ®Google Scholar
• Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 2006;38:218–245.
   PubMed Web of Science ®Google Scholar
• Del Pozo-Rodríguez A, Delgado D, Gascón AR, et al. Lipid nanoparticles as drug/gene delivery systems to the retina. J Ocul Pharmacol Ther. 2013;29(2):173–188.
   PubMed Web of Science ®Google Scholar
• EMA. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. Draft. EMA/CAT/80183/2014. London: European Medicines Agency; 2015.
   Google Scholar
• Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med. 2008;358:2231–2239.
   PubMed Web of Science ®Google Scholar
• Banin E, Bandah-Rozenfeld D, Obolensky A, et al. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. Hum Gene Ther. 2010;21:1749–1757.
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA. 2008;105:15112–15117.
   PubMed Web of Science ®Google Scholar
• Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008;358:2240–2248.
   PubMed Web of Science ®Google Scholar
• Kumar-Singh R. Barriers for retinal gene therapy: separating fact from fiction. Vis Res. 2008;48:1671–1680.
   PubMed Web of Science ®Google Scholar
• Provost N, Le Meur G, Weber M, et al. Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol Ther. 2005;11:275–283.
   PubMed Web of Science ®Google Scholar
• Cai X, Conley S, Naash M. Nanoparticle applications in ocular gene therapy. Vision Res. 2008;48:319–324.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Gascón A, Solinís MA, Del Pozo-Rodríguez A, et al. Lipid nanoparticles for gene therapy. US 20120183589 A1. 2012.
   Google Scholar
• Rodríguez-Gascón A, Solinís MA, Del Pozo-Rodríguez A, et al. Lipid nanoparticles for treating ocular diseases. WO 2012085318 A1. 2012.
   Google Scholar
• Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012;163:34–45.
   PubMed Web of Science ®Google Scholar
• Beloqui A, Má S, Rodríguez-Gascón A, et al. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomed. 2016;12:143–161.
   PubMed Web of Science ®Google Scholar
• Böhm M, Avgitidou G, El Hassan E, et al. Liposomes: a new non-pharmacological therapy concept for seasonal-allergic-rhinoconjunctivitis. Eur Arch Otorhinolaryngol. 2012;269:495–502.
   PubMed Web of Science ®Google Scholar
• Hofauer B, Bas M, Manour N, et al. Effekt liposomaler lokaltherapie auf die Sicca-Symptomatik des primären Sjögren-Syndroms. HNO. 2013;61:921–927.
   PubMed Web of Science ®Google Scholar
• Díaz-Llopis M, Martos MJ, España E, et al. Liposomally entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Experimental toxicity and pharmacokinetics, and clinical trial. Doc Ophthalmol. 1992;82:297–305.
   PubMed Web of Science ®Google Scholar
• Kalita D, Shome D, Jain VG, et al. In vivo intraocular distribution and safety of periocular nanoparticle carboplatin for treatment of advanced retinoblastoma in humans. Am J Ophthalmol. 2014;157:1109–1115.
   PubMed Web of Science ®Google Scholar